


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	09/393,590	
			Filing Date	09/09/1999	
			First Named Inventor	MOYER, Elizabeth	
			Group Art Unit	1645	
			Examiner Name	S. Devi	
			Attorney Docket Number	211-US-NEW	
Sheet	1	of	2		

[illegible]

FOREIGN PATENT DOCUMENTS							
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
SP	BA		WO 95/05842		Johns Hopkins Univ	03/02/1995	
SP	BB		WO 93/05800		Allergan Inc.	04/01/1993	
SP	BC		WO 96/39167		Pearce, B.L.	12/12/1996	
SP	BD		WO 94/00481		Associated Synapse Biologics	01/06/1994	
SP	BE		WO 97/35604		Wisconsin Alumni Research Foundation	10/02/1997	
SP	BF		WO 96/11699		Wisconsin Alumni Research Foundation	04/25/1996	

Examiner Signature	<i>SD</i>	Date Considered	<i>October 2000</i>
-----------------------	-----------	--------------------	---------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANTS

(use as many sheets as necessary)

Sheet 2 of 2

**Complete if Known**

<b>Application Number</b>	09/393,590
<b>Filing Date</b>	09/09/1999
<b>First Named Inventor</b>	MOYER, Elizabeth
<b>Group Art Unit</b>	1645
<b>Examiner Name</b>	S. Devi
<b>Attorney Docket Number</b>	211-US-NEW

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
SR	BG		0 593 176 A2		Wisconsin Alumni Research Foundation	09/28/1992		
SR	BH		WO 95/17904		Allergan, Inc.	07/06/1993		
SR	BI		WO 95/17904		Allergan, Inc.	07/06/1995		
SR	BJ		WO 94/28923		Allergan, Inc.	12/22/1994		
SR	BK		WO 94/28922		Allergan, Inc.	12/22/1994		
SR	BL		WO 95/28171		Mt. Sinai School of Medicine	10/26/1995		
SR	BM		WO 95/17904		Allergan, Inc.	07/06/1995		
SR	BN		WO 95/30431		Binder, W.J.	11/16/1995		
SR	BO		WO 96/39167		Pearce, B.L.	12/31/1996		

Examiner  
Signature

SD

Date	
Considered	

November 2000

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box

+



PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

### Complete if Known

Application Number	09/393,590
Filing Date	09/09/1999
First Named Inventor	Elizabeth MOYER
Group Art Unit	1645
Examiner Name	S. Devi
Attorney Docket Number	211-US-NEW

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CA	99	FIRST, E.R., ET AL., "Dose Standardisation of Botulinum Toxin," The Lancet, vol. 343, p. 1035, ( April 23, 1994).	
CB	99	GARTLAN, M.G., ET AL., "Crystalline preparation of botulinum toxin type A (Botox): Degradation in potency with storage," Otolaryngology, vol. 108, p. 135-140, (1993).	
CC	99	HAMBLETON, B.C., ET AL., "Production, Purification and Toxoiding of Clostridium Botulinum Type A Toxin," Biomedical Aspects of Botulism, Academic Press (US), p. 247-260, (1981).	
CD	99	KADIS, S., ET AL., "Microbial Toxins," Bacterial Protein Toxins, Academic Press (US), p. 1-68, (1971).	
CE	99	LAMANNA, C., ET AL., "The Isolation of Type B Botulinum Toxin," Journal of Bacteriology, (US), vol. 54, p. 575-584, (1947).	
CF	99	MELLING, J., ET AL., "Clostridium Botulinum Toxins: Nature and Preparation for Clinical Use," Eye, vol. 2, p. 16-23, (1988).	
CG	99	SCHANTZ, E.J., ET AL., "Microbiological Methods," Journal of the AOAC (UK), Association of Official Analytical Chemists, Vol. 61 ( No. 1), p. 96-99, (1978).	
CH	99	SCHANTZ, E.J., ET AL., "Quality of Botulinum Toxin For Human Treatment," Botulinum and Tetanus Neurotoxins, B.R. Dasgupta, ed., Plenum Press, p. 657-659, (1993).	
CI	99	SLOOP, R.R., MD, ET AL., "Human response to botulinum toxin injection: Type B compared with type A," The American Academy of Neurology (US), vol. 49, p. 189-194, ( July 27, 1997).	
CJ	99	SUGII, S., ET AL., "Correlation Between Oral Toxicity and In Vitro Stability of Clostridium botulinum Type A and B Toxins of Different Molecular Sizes," Infection and Immunity, American Society of Microbiology (US), vol. 16, p. 910-914, (1977).	
CK	99	WRIGHT, G.P., "The Neurotoxins of Clostridium Botulinum and Clostridium Tetani," Pharmacology, vol. 7, p. 413-465, (1955).	

Examiner Signature	99	Date Considered	October 2000
--------------------	----	-----------------	--------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.




+

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED  
AUG 2 1964



October 2000

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.